Business Context and Reporting Period
This Form 8-K, dated December 29, 2022, reports the completion of a business combination between Gemini Therapeutics, Inc. (the "Company") and Disc Medicine Opco, Inc. ("Disc"). Effective December 29, 2022, the Company changed its name to Disc Medicine, Inc. and its ticker symbol on the Nasdaq Global Market changed from "GMTX" to "IRON". The Company is now a clinical-stage biopharmaceutical company focused on hematologic diseases.
Key Financial Metrics and Capital Structure
This filing details the structural and capital changes resulting from the merger rather than operating financial performance metrics (revenue, profit, cash flow) for the period, which are referenced in attached exhibits.
- Stock Split: A 1-for-10 reverse stock split was effected on December 29, 2022.
- Shares Outstanding: Approximately 16,923,285 shares of common stock were outstanding immediately following the merger.
- Merger Consideration: The Company issued approximately 12,533,557 shares to Disc stockholders based on an exchange ratio of 0.1096 shares of Company common stock for each share of Disc common stock.
- Roche Issuance: The Company issued 482,313 shares of common stock to F. Hoffmann-La Roche Ltd. and affiliates for no additional consideration, representing approximately 2.85% of the post-merger capitalization.
- Contingent Value Rights (CVRs): Pre-merger stockholders received one CVR for each share held, entitling them to potential future payments in Company stock based on proceeds from the disposition of legacy assets.
Material Changes Versus Prior Period
The filing represents a fundamental transformation of the registrant:
- Corporate Identity: The registrant formerly known as Gemini Therapeutics, Inc. is now Disc Medicine, Inc.
- Board Composition: The board was reconstituted to nine members. Five former directors (Carl Gordon, David Lubner, Tuyen Ong, Jason Rhodes, Jim Tananbaum) resigned. New directors appointed include Donald Nicholson (Executive Chairman), John Quisel, Mona Ashiya, Kevin Bitterman, Jay Backstrom, Mark Chin, Liam Ratcliffe, and William White.
- Executive Leadership: John Quisel was appointed CEO; Joanne Bryce was appointed CFO; William Savage was appointed CMO. Former Interim CEO Georges Gemayel and former CFO Brian Piekos ceased to be officers.
- Capitalization: The authorized share count was reduced to 100,000,000 shares.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Strategy: The Company's business is now primarily the business of Disc, focused on the discovery and development of novel treatments for serious hematologic diseases. The filing contains forward-looking statements regarding clinical trial timelines, regulatory strategies, and the integration of Disc and Gemini assets.
Risks and Contingencies:
- Forward-Looking Statements: The filing includes extensive disclaimers regarding uncertainties in clinical trial results, regulatory approvals, capital adequacy, and the integration of the merger.
- Legal Proceedings: Risks include potential legal proceedings related to the merger agreement.
- Capital Requirements: The Company faces risks regarding the adequacy of capital to support future operations and clinical trials.
- CVR Uncertainty: There is no assurance that payments under the Contingent Value Rights Agreement will be made, as they depend on the receipt of proceeds from legacy asset dispositions.
Unusual Items: The issuance of shares to Roche for no additional consideration and the creation of CVRs for legacy shareholders are significant non-operating capital events.
Important Facts for Investor Verification
- Trading Symbol Change: Verify trading under the new ticker "IRON" on Nasdaq effective December 30, 2022.
- Share Count Adjustment: Confirm holdings reflect the 1-for-10 reverse stock split and the issuance of new shares to Disc shareholders and Roche.
- CVR Terms: Review the Contingent Value Rights Agreement (Exhibit 10.2) to understand the conditions under which legacy shareholders may receive additional shares.
- Executive Compensation: Note the new employment agreements for the CEO, CFO, and CMO, which include significant change-in-control severance provisions (e.g., 18 months base salary for CEO upon termination within the Change in Control Period).
- Financial Statements: Refer to Exhibits 99.5 and 99.6 for the audited and unaudited financial statements of Disc, as this 8-K does not contain the full financial data tables.